Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 56, Issue , 2015, Pages 75-80

  Lian, Jiamei ^a   Huang, Xu Feng ^a,b   Pai, Nagesh ^a   Deng, Chao ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Betahistine; Dopamine receptor; Olanzapine; Receptor binding; Serotonin receptor

Indexed keywords

BETAHISTINE; DOPAMINE 2 RECEPTOR; KETANSERIN; MESULERGINE; OLANZAPINE; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; RACLOPRIDE; BENZODIAZEPINE DERIVATIVE; HISTAMINE AGONIST; PROTEIN BINDING; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BODY WEIGHT; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HISTOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PUTAMEN; RAT; RECEPTOR BINDING; CHRONIC DRUG ADMINISTRATION; RECEPTOR UPREGULATION; SEROTONINERGIC TRANSMISSION; ANIMAL; BRAIN; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; GENE EXPRESSION REGULATION; METABOLISM; NONPARAMETRIC TEST; SPRAGUE DAWLEY RAT;

ANIMALS; AUTORADIOGRAPHY; BENZODIAZEPINES; BETAHISTINE; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GENE EXPRESSION REGULATION; HISTAMINE AGONISTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC; TRITIUM;

EID: 84906771313     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.08.006     Document Type: Article

References (50)

1. Abbas A.I., Yadav P.N., Yao W.D., Arbuckle M.I., Grant S.G., Caron M.G., et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 2009, 29:7124-7136.
2. Aravagiri M., Teper Y., Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999, 20:369-377.
3. Botta L., Mira E., Valli S., Zucca G., Benvenuti C., Fossati A., et al. Effects of betahistine and of its metabolites on vestibular sensory organs. Acta Otorhinolaryngol Ital 2001, 21:24-30.
4. Choi S., DiSilvio B., Unangst J., Fernstrom J.D. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 2007, 81:1024-1030.
5. Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013, 42:545-563.
6. 3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1-4.
7. Deng C., Lian J., Pai N., Huang X.F. Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model. J Psychopharmacol 2012, 26:1279-1291.
8. Di Matteo V., De Blasi A., Di Giulio C., Esposito E. Role of 5-HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci 2001, 22:229-232.
9. du Bois T.M., Deng C., Bell W., Huang X.F. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience 2006, 139:1397-1403.
10. du Bois T.M., Hsu C.W., Li Y., Tan Y.Y., Deng C., Huang X.F. Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem Res 2008, 33:1224-1231.
11. FDA Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers 2005, U.S. FDA Center for Drug Evaluation and Research.
12. Ferrada C., Ferre S., Casado V., Cortes A., Justinova Z., Barnes C., et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008, 55:190-197.
13. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.-C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009, 43:620-626.
14. Ginovart N., Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012, 27-52.
15. Han M., Huang X.F., du Bois T.M., Deng C. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience 2009, 164:1754-1763.
16. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
17. Howes O., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry 2012, 69:776-786.
18. Kang K., Huang X.F., Wang Q., Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:867-871.
19. Kantrowitz J.T., Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008, 7:761-769.
20. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1081-1090.
21. Kim S.F., Huang A.S., Snowman A.M., Teuscher C., Snyder S.H. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007, 104:3456-3459.
22. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008, vol. 172:199-212. Elsevier.
23. Lambert T. Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Aust Prescr 2011, 34:97-99.
24. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
25. Lian J., Huang X.-F., Pai N., Deng C. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Prog Neuropsychopharmacol Biol Psychiatry 2013, 47:62-68.
26. Lian J., Huang X.-F., Pai N., Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One 2014, 9:e104160.
27. Lieberman J., Stroup T., Swartz M. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
28. Meltzer H., Massey B. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011, 11:59-67.
29. Nasrallah Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
30. Panula P., Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci 2013, 14:472-487.
31. Patel J.K., Buckley P.F., Woolson S., Hamer R.M., McEvoy J.P., Perkins D.O., et al. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 2009, 111:9-16.
32. Paxinos G., Watson C. The Rat Brain in Sterotaxic Coordinates 2007, Academic Press.
33. 3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005, 20:101-103.
34. Poyurovsky M., Fuchs C., Pashinian A., Levi A., Weizman R., Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl) 2013, 226:615-622.
35. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
36. Reynolds G.P., Templeman L.A., Zhang Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1021-1028.
37. Samaha A.-N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007, 27:2979-2986.
38. Seeman M.V. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009, 35:937-948.
39. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011, 17:118-132.
40. Szelag A., Trocha M., Merwid-Lad A. Betahistine inhibits food intake in rats. Pol J Pharmacol 2001, 53:701-707.
41. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001, 297:711-717.
42. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002, 161:263-270.
43. Tarricone I., Ferrari Gozzi B., Serretti A., Grieco D., Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010, 40:187-200.
44. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002, 7:317-321.
45. Treuer T., Pendlebury J., Lockman H., Bushe C., Karagianis J., Raskin J., et al. Weight gain risk factor assessment checklist: overview and recommendation for use. Neuroendocrinol Lett 2011, 32:199-205.
46. Vazquez-Bourgon J., Arranz M.J., Mata I., Pelayo-Teran J.M., Perez-Iglesias R., Medina-Gonzalez L., et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010, 175:189-194.
47. Volk D. Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci 2010, 4:485-508.
48. Weston-Green K., Huang X.-F., Deng C. Sensitivity of the female rat to olanzapine-induced weight gain-far from the clinic?. Schizophr Res 2010, 116:299-300.
49. Weston-Green K., Huang X.-F., Deng C. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 2011, 217:337-346.
50. Zhang J.P., Malhotra A.K. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011, 7:9-37.